Trial Profile
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 20 Nov 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 20 Nov 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.
- 18 Nov 2022 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.